Cerebrospinal fluid α-synuclein contributes to the differential diagnosis of Alzheimer's disease.

ABSTRACT:

Introduction

The ability of Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers (amyloid β peptide 1-42, total tau, and phosphorylated tau) to discriminate AD from related disorders is limited. Biomarkers for other concomitant pathologies (e.g., CSF α-synuclein [α-syn] for Lewy body pathology) may be needed to further improve the differential diagnosis.

Methods

CSF total α-syn, phosphorylated α-syn at Ser129, and AD CSF biomarkers were evaluated with Luminex immunoassays in 367 participants, followed by validation in 74 different neuropathologically confirmed cases.

Results

CSF total α-syn, when combined with amyloid β peptide 1-42 and either total tau or phosphorylated tau, improved the differential diagnosis of AD versus frontotemporal dementia, Lewy body

SUBMITTER: Shi M 

PROVIDER: S-EPMC6097943 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature